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Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed
patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with
highly active disease. The role of these biomarkers in relapsing disease is unclear.
Methods
Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in
serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients).
Epidemiological, clinical and laboratory data were available for all visits.
Results
At the first visit, 80% of patients were using glucocorticoids and 68% additional immunosup-
pressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG
scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were use-
ful to discriminate between active disease and remission. Patients treated with prednisone
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had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids ir-
respective of disease activity. Use of immunosuppressive agents was not associated with
biomarker levels.
Conclusions
Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differenti-
ate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains
a challenge especially during times of glucocorticoid use.
Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) is a rare systemic vascu-
litis almost exclusively arising in asthma patients [1]. Although EGPA can occur in any organ
system, the most frequent disease manifestations are confined to the respiratory tract and pe-
ripheral nervous system. Skin, gastro-intestinal tract, and cardiac involvement are also com-
mon, with the latter being the major determinant of mortality in the long- term [2]. Marked
eosinophilia is an extremely common feature of EGPA. Anti-neutrophil cytoplasmic antibodies
(ANCA) are present in one third of patients at diagnosis and are associated with the presence
of glomerulonephritis [3]. On a microscopic level, EGPA typically causes an eosinophil- rich,
granulomatous, necrotizing vasculitis [4]. Mild disease is usually treated with glucocorticoids
alone, whereas severe disease requires additional therapy with immunosuppressive drugs such
as cyclophosphamide [5,6].
Relapses are common in EGPA and clinical experience suggests that severe flares are usually
accompanied by blood eosinophilia [7]. However, intermittent elevation of eosinophil count
without change in clinical activity of EGPA itself is also frequent. Moreover, discriminating dis-
ease activity from worsening of underlying asthma and sinusitis is challenging. Thus, biomark-
ers supporting the diagnosis of disease flares in EGPA would be extremely helpful. In prior
studies of untreated patients with EGPA with active disease, we found several potential bio-
markers of disease activity including serum levels of eotaxin-3, TARC/CCL17, and IgG4 [8–
10]. In the current study, we investigated a panel of biomarkers in a prospective, longitudinal
EGPA cohort to determine the marker’s value in identifying relapsing disease.
Methods
Study patients
Twenty-five patients enrolled between 2006 and 2012 in the Vasculitis Clinical Research Con-
sortium (VCRC) Longitudinal Study of EGPA were selected for this analysis. The VCRC is a
multicenter research infrastructure supported by US National Institutes of Health (NIH). Pa-
tients fulfilled the 1990 American College of Rheumatology (ACR) classification criteria for
Churg-Strauss syndrome [11]. All subjects were enrolled using protocols and written informed
consent documents approved by local institutional review boards/ethics committees at all insti-
tutions at which participants were recruited: Boston University (Boston University Medical
Campus IRB), University of South Florida (USF IRB), McMaster University (McMaster Re-
search Ethics Board), Mount Sinai Hospital Toronto (The Mount Sinai Research Ethics
Board), Cleveland Clinic (IRB Cleveland Clinic Foundation), University of Utah (University of
Utah IRB), University of Pittsburgh (University of Pitts burgh IRB), Johns Hopkins University
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(The Johns Hopkins Medicine IRB), Mayo Clinic (Mayo Clinic Institutional Review Board)
and University of Pennsylvania (University of Pennsylvania IRB).
Clinicians with expertise in vasculitis performed comprehensive clinical assessments at each
visit. Features of disease directly attributable to EGPA were recorded using standardized data
collection forms. Summary measures of disease activity at each visit included calculation of the
Birmingham Vasculitis Activity Score (BVAS) and the BVAS for Wegener’s Granulomatosis
(BVAS/WG) [12,13]. BVAS and BVAS/WG scores indicate new or worse disease activity with-
in the prior four weeks. In addition, physician-investigators categorically rated patients’ disease
activity within the past four weeks as either remission, mild, moderate or high disease activity.
For statistical analyses, we pooled data from patients’ visits with mild, moderate and high dis-
ease activity into one category named “active”. All patients’ visits categorized as active revealed
by BVAS/WG and BVAS. Physician global assessment of disease activity within the prior 28
days was evaluated on a 0–10 Likert scale (BVAS/WG PGA). Worsening asthma alone in the
absence of involvement of other organ systems was not sufficient to classify a patient as active
EGPA.
All 18 patients with EGPA in the VCRC cohort (as of 2012) who had a clinical relapse and
who had additional samples taken during remission were investigated. Serum samples were re-
trieved at the relapse visits, and further sampling (1–7 per patient) was performed at visits con-
ducted in phases of remission 1–8 months before and/or 3–24 months after a flare. Seven
patients with EGPA without clinical relapse were studied in a similar way: 2–5 serum samples
across 3–12 months.
Biomarker studies
Results of the following tests were obtained for all patients at all study visits: Erythrocyte sedi-
mentation rate (ESR, mm/hour), C-reactive protein (CRP, mg/L), and eosinophil count were
measured at the VCRC sites using standard methods. Serum levels of eotaxin-3 and TARC/
CCL17 were determined by ELISA (both R&D Systems, Minneapolis, MN, USA) as previously
described [8,10]. Serum levels of total IgG and IgG4 were analyzed by nephelometry.
Statistical analysis
Descriptive statistics were used to summarize data. The Kolmogorov-Smirnov test was used to
check for normality. For data with a normal distribution, mean ± standard deviation is pre-
sented whereas for non-normally distributed data the median and range is reported. We used
the Mann-Whitney U test for comparisons of (not normally distributed) data. Proportions
were analyzed by chi-square or Fisher’s exact test, as appropriate. Statistical analysis was per-
formed using SPSS version 21 (SPSS Inc., Chicago, IL).
Multivariate inclusive logistic regression (maximum likelihood method) models were con-
ducted to investigate the association between biomarkers, disease activity and glucocorticoid
use. There was insufficient power to perform a repeated measurement model due to the low
number of patients and visits. Therefore, we analyzed each visit as if it was an independent case
and adjusted for possible clustering of findings within patients including the factor patient into
the regression model. We applied either disease activity (active or remission as determined by
treating physicians), the use of glucocorticoids (yes or no) or treatment with immunosuppres-
sive agents (yes or no) as variables of primary interest. Glucocorticoids, immunosuppressive
agents and disease activity were included as covariates in these models. Goodness of fit was
tested with Hosmer-Lemeshow statistics and for sensitivity analysis we excluded cases produc-
ing low/high DFBETAs and/or large Cook values.
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Results
Patient Characteristics
We analyzed 105 visits of 25 patients with EGPA (median 4 visits per patient, range 2–8)
(Table 1). Mean age of the patients was 49.7 ± 13 years with similar numbers of males and fe-
males. At their first visits, 20 patients (80%) were receiving prednisone and 17 (68%) had addi-
tional immunosuppressive therapies (9 methotrexate, 7 azathioprine and 1 mycophenolate
mofetil). Remission was observed in 87 (83%) visits, while disease flares were seen at 18 (17%)
visits. Five of the 18 flares observed were characterized as moderate or severe, while the other
13 were regarded as mild. No patient had more than one flare. Median BVAS at flare visits was
4 (range 0–18) and median BVAS/WG was 2 (range 1–4). EGPA symptoms most commonly
observed in relapsing patients were: constitutional symptoms, musculoskeletal pain, sinusitis
and peripheral neuropathy. Cardiovascular events, renal and gastrointestinal disease manifes-
tations were rare or absent during relapsing disease in this cohort.
Table 1. Clinical manifestations of study patients with EGPA.
Clinical characteristics Remission, n = 87 Active, n = 18
Constitutional symptoms, n (%) 1 (1.2) 6 (33.3)***
Arthralgia/Arthritis, n (%) 0 4 (22.2) ***
Myalgia/Myositis, n (%) 0 1 (5.6)
Skin, n (%) 2 (2.3) 2 (11.2)
Ear nose throat, n (%) 2 (2.3) 5 (27.8)**
Cardiovascular Events, n (%) 0 1 (5.6)
Gastrointestinal, n (%) 1 (1.2) 0
Pulmonary, n (%) 2 (2.3) 2 (11.2)
Asthma, n (%) 19 (21.8) 3 (16.7)
Kidney
Proteinuria, n (%) 7 (8.0) 3 (16.7)
Hematuria, n (%) 6 (6.9) 2 (11.1)
RBC casts, n (%) 3 (3.4) 1 (5.6)
Elevated serum creatinine, n (%) 3 (3.4) 1 (5.6)
Creatinine, median (range) [mg/dL] 0.8 (0–1.6) 0.8 (0.6–1.7)
Peripheral neuropathy, n (%) 2 (2.3) 3 (16.7)*
BVAS/WG PGA, median (range) 0 (0) 2.5 (1–8) ‡
BVAS score, median (range) 0 4 (0–18) ‡
BVAS/WG score, median (range) 0 2 (1–4) ‡
IgE, median (range) 16.0 (0.1–1926.0) 0 (0.1–427.0)
WBC, median (range) 7.3 (3.2–13.9) 8.8 (4.8–12.8) †
EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); BVAS: Birmingham Vasculitis Activity
Score; BVAS/WG: BVAS for Wegener’s Granulomatosis; n (%), number and percentage of patients (out of
those with known outcome) with manifestation since previous visit
*p<0.05
**p<0.01
***p<0.001 according to Fisher’s exact test (not corrected for multiple testing).
† p<0.05
‡ p<0.001 according to Mann Whitney U test (not corrected for multiple testing)
doi:10.1371/journal.pone.0121737.t001
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Serum levels of eotaxin-3, TARC/CCL17 and IgG4 in patients with
EGPA
Serum levels of eotaxin-3, TARC/CCL17, IgG4, and IgG4/IgG ratio did not discriminate be-
tween periods of remission and active disease within individual patients (Table 2), even after
adjustment for prednisone use. Similarly, ESR, CRP, and eosinophil count also failed to differ-
entiate between active and inactive disease.
Next, we asked whether biomarker levels differed between groups defined by use of predni-
sone or immunosuppressive agents. Results are detailed in Table 3 and Table 4. As expected,
eosinophil counts were higher in non-users of prednisone than in users, but ESR, CRP, serum
TARC/CCL17 and IgG4/IgG ratio was not significantly different. Eotaxin-3 levels were also in-
creased in patients not on prednisone. IgG4 levels were lower in patients not taking prednisone
according to unadjusted analysis; however, the difference was not significant after correction
for disease activity and use of immunosuppressive agents. Similarly, we observed lower
eotaxin-3 levels and a higher ESR in patients on immunosuppressive agents in unadjusted anal-
ysis, whereas in the multivariate model, the difference was not significant.
Discussion
Little is known about serologic markers of activity in relapsing patients with EGPA. Defining
active disease in EGPA is especially challenging because almost all patients have underlying in-
flammatory disease that does not necessarily indicate activity of EGPA per se, such as asthma
and symptoms of rhinosinusitis. Symptoms of asthma may recur together with signs of vasculi-
tis in patients with active EGPA, a worsening of asthma alone, however, is usually insufficient
to diagnose a relapse of EGPA.
Many patients are prescribed chronic low dose of prednisone to help with a control of asth-
ma rather than to treat vasculitis or parenchymal eosinophilic inflammation. When both upper
and lower respiratory symptoms recur upon prednisone tapering, it is often difficult to decide
whether vasculitis itself is active. Blood eosinophil counts are reduced by even low doses of glu-
cocorticoids and are therefore also difficult to interpret in clinical practice. Conversely, elevated
eosinophil counts may occur without return of vasculitis.
We studied a set of potential biomarkers (Eotaxin-3, TARC/CCL17, IgG4, and IgG4/IgG
ratio) for disease relapse in a prospective, well-defined EGPA cohort. All biomarkers have been
previously identified in newly- diagnosed patients with EGPA. TARC/CCL17, a chemokine re-
sponsible for Th2 cell recruitment, is elevated in the serum of active patients with EGPA corre-
lating with disease activity [8]. Further, eotaxin-3 is an eosinophil-attracting chemokine
Table 2. Serum biomarkers of patients with EGPA in remission and at relapse.
Serum parameter Remission (n = 87) Active (n = 18) MWU LR
Eotaxin-3 [pg/ml] 0 (0–555.5) 1.5 (0–482.4) 0.25 0.90
TARC/CCL 17 [pg/ml] 304.2 (77.1–4549.4) 391.9 (100.2–2684.6) 0.57 0.35
IgG4 [mg/dL] 45.1 (0–479.0) 22.0 (10.0–332.0) 0.50 0.30
IgG4/IgG ratio*100 6.3 (0–32.0) 3.2 (1.0–29.0) 0.26 0.54
ESR [mm/hour] 5.0 (1–40.0) 8.5 (1–40.0) 0.64 0.074
CRP [mg/L] 2.5 (0.1–32.9) 1.7 (0.1–12.3) 0.74 0.49
Eosinophils (%) 4.0 (0.1–50.0) 4.3 (0.8–33.6) 0.86 0.86
Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); LR, Logistic regression analysis
as described in Materials and Methods; MWU, Mann Whitney U test; n, number of visits
doi:10.1371/journal.pone.0121737.t002
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elevated in EGPA but not in other eosinophilic or vasculitic disorders [14]. IgG4 is the least
abundant IgG subclass. The function of IgG4 is currently unclear but it is associated with a Th2
immune response [9]. IgG4 is highly elevated in active EGPA at disease presentation and de-
creases during remission. However, prior studies of IgG4 in EGPA included patients who were
newly diagnosed and most patients were not on immunosuppressive therapy at the time of test-
ing. Therefore, we studied a real-life cohort of established patients with EGPA focusing on
relapsing disease.
In this cohort, most disease flares were mild in the observational period and we could not
find any significant differences in routine serologic markers such as ESR, CRP, or eosinophil
count. These findings have been corroborated in a more detailed analysis of the same VCRC
cohort using data from 141 patients with EGPA with longitudinal follow-up [15]. Organ mani-
festations of relapsing patients were, however, typical for EGPA with a predominance of consti-
tutional and respiratory symptoms, ENT manifestations and neuropathic pain. Levels of
eotaxin-3, TARC/CCL17, IgG4, and IgG4/IgG ratio all failed to discriminate reliably between
active and inactive patients. Prednisone clearly modulated serum levels of eotaxin-3 and eosin-
ophils independent of disease activity. Overall, the frequent use of prednisone in EGPA argues
against a significant role for these biomarkers in follow-up clinical care. Whether immunosup-
pressive agents also influence levels of the measured biomarkers is unclear. In our cohort, no
statistically significant association was observed in the multivariate analysis; however, the num-
ber of patients on immunosuppressive agents was small and several agents with potentially
Table 3. Serum biomarkers of patients with EGPA based on prednisone usage at time of study visit.
Serum parameters No pred. use (n = 24) Pred. use (n = 81) MWU LR
Eotaxin-3 [pg/ml] 9.7 (0–549.8) 0 (0–555.5) 0.004 0.021
TARC/CCL17 [pg/ml] 393.6 (129.3–1918.0) 285.5 (77.1–4549.4) 0.18 0.67
IgG4 [mg/dL] 21.5 (7.0–281.0) 47.0 (7.0–479.0) 0.038 0.099
IgG4/IgG ratio*100 3.4 (0.1–22.0) 6.0 (1.0–32.0) 0.52 0.19
ESR [mm/1st hour] 5.0 (1–40.0) 5.0 (1–40) 0.80 0.084
CRP [mg/L] 2.9 (0.1–32.9) 2.2 (0.1–21.0) 0.41 0.20
Eosinophils (%) 8.0 (1–50.0) 4.0 (0.1–43.0) <0.001 0.006
Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); LR, Logistic regression analysis
as described in Materials and Methods; MWU, Mann Whitney U test; n, number of visits; pred., prednisone
doi:10.1371/journal.pone.0121737.t003
Table 4. Serum biomarkers of patients with EGPA based on use of immunosuppressive agents at time of study visit.
Serum parameters No immunosuppr. use (n = 32) Immunosuppr. use (n = 73) MWU LR
Eotaxin-3 [pg/ml] 1.6 (0–555.5) 0 (0–92.2) 0.015 0.06
TARC/CCL17 [pg/ml] 386.3 (97.1–2684.6) 288.3 (98.8–4549.4) 0.28 0.47
IgG4 [mg/dL] 19.5 (8–479) 62.4 (7–337) 0.15 0.74
IgG4/IgG ratio*100 2.9 (1–32.0) 7.1 (1–28.0) 0.079 0.58
ESR [mm/1st hour] 4 (1–20) 8 (1–40) 0.031 0.07
CRP [mg/L] 3.5 (0.1–21.0) 2.0 (0.1–32.9) 0.23 0.42
Eosinophils (%) 5.5 (0.7–33.6) 4.0 (0.1–50.0) 0.46 0.41
Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); immunosuppr.,
immunosuppressive agents (9 patients were on methotrexate, 7 on azathioprine and 1 on mycophenolate mofetil); LR, Logistic regression analysis as
described in Materials and Methods; MWU, Mann Whitney U test; n, number of visits
doi:10.1371/journal.pone.0121737.t004
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different impact on biomarkers were used. Larger studies are required to investigate the possi-
ble association between immunosuppressive drugs and biomarkers in EGPA.
Our study has some important strengths. The study subjects were part of a standardized,
prospective, longitudinal data collection with an extensive dataset. In addition, all patients
were recruited in expert centers and assessed by clinicians familiar with this rare disease and its
clinical manifestations.
Our study has also some limitations: The sample size of our cohort was small compared to
biomarker studies in other rheumatic diseases. However, given the rarity of EGPA, it is chal-
lenging to assemble larger cohorts for such a project. Most relapses were mild lacking serious
clinical manifestations (such as cardiovascular, gastrointestinal and central nervous system in-
volvement), and we cannot exclude the possibility that some patients had their prednisone
dose increased before serum sampling. Yet, both of these facts reflect the clinical reality of the
disease and its management. Moreover, most patients were already on glucocorticoids at the
initiation of study, and detailed information about doses of prednisone and immunosuppres-
sive agents used prior to enrollment were limited, making the analysis of associations between
biomarkers and these factors difficult.
In summary, defining biomarkers for relapsing disease in EGPA remains difficult. Novel
biomarkers tested in this study could not reliably discriminate active and inactive disease. The
potential impact of glucocorticoids and other immunosuppressive drugs with available and po-
tential biomarkers remains a major challenge in the study of biomarkers for EGPA.
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